San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug market in February following revealing promising information from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection As well as in March